Get the Stockscreener App
3.54
1.14%
0.04
Scpharmaceuticals Inc stock is traded at $3.54, with a volume of 304.27K.
It is up +1.14% in the last 24 hours and down -2.21% over the past month.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.
See More
Previous Close:
$3.50
Open:
$3.53
24h Volume:
304.27K
Relative Volume:
0.75
Market Cap:
$177.14M
Revenue:
$17.63M
Net Income/Loss:
$-57.71M
P/E Ratio:
-2.6617
EPS:
-1.33
Net Cash Flow:
$-60.45M
1W Performance:
+4.73%
1M Performance:
-2.21%
6M Performance:
-18.62%
1Y Performance:
-43.54%
1-Day Range:
$3.45
$3.60
1-Week Range:
$3.325
$3.60
52-Week Range:
$3.075
$6.60
Scpharmaceuticals Inc Stock (SCPH) Company Profile
Name
Scpharmaceuticals Inc
Sector
Industry
Phone
617-517-0730
Address
25 BURLINGTON MALL ROAD, SUITE 203, BURLINGTON, MA
Compare SCPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCPH
Scpharmaceuticals Inc
|
3.54 | 177.14M | 17.63M | -57.71M | -60.45M | -1.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
402.70 | 103.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
712.33 | 78.28B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
615.00 | 36.77B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.31 | 30.35B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.95 | 27.32B | 3.30B | -501.07M | 1.03B | -2.1146 |
Scpharmaceuticals Inc Stock (SCPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-07-23 | Initiated | Craig Hallum | Buy |
| Dec-01-22 | Initiated | Cowen | Outperform |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Oct-11-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-02-22 | Initiated | Maxim Group | Buy |
| Sep-09-21 | Initiated | SVB Leerink | Mkt Perform |
| Oct-15-19 | Initiated | H.C. Wainwright | Buy |
| Jan-30-19 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
View All
Scpharmaceuticals Inc Stock (SCPH) Latest News
scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Purchased by State Street Corp - Defense World
scPharmaceuticals Inc.'s (NASDAQ:SCPH) Shift From Loss To Profit - Yahoo Finance
Sanctuary Advisors LLC Takes $75,000 Position in scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
27,169 Shares in scPharmaceuticals Inc. (NASDAQ:SCPH) Bought by XTX Topco Ltd - Defense World
BNP Paribas Financial Markets Has $26,000 Stock Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
Charles Schwab Investment Management Inc. Sells 3,312 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
SC Pharmaceuticals Inc (SCPH-Q) QuotePress Release - The Globe and Mail
The Manufacturers Life Insurance Company Invests $57,000 in scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
2 "Strong Buy"-Rated Biotech Stocks With 303% To 446% Upside Potential - Barchart
Tscan Therapeutics Inc (TCRX-Q) QuotePress Release - The Globe and Mail
Head to Head Survey: Cyclerion Therapeutics (NASDAQ:CYCN) vs. scPharmaceuticals (NASDAQ:SCPH) - Defense World
Wearable Injector Market Growth in Future Scope 2024-2031 | - openPR
ScPharmaceuticals Stock Falls After Noting Possible FDA Submission Delay - MarketWatch
MetLife Investment Management LLC Grows Stock Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
SCPH (scPharmaceuticals) 9-Day RSI : 45.28 (As of Dec. 04, 2024) - GuruFocus.com
Jefferies cuts scPharmaceuticals stock target, keeps buy rating on Q3 results - Investing.com UK
Suvretta Capital Management LLC Makes New $9.34 Million Investment in scPharmaceuticals Inc. (NASDAQ:SCPH) - MarketBeat
Rubric Capital Management LP Boosts Stake in scPharmaceuticals Inc. (NASDAQ:SCPH) - MarketBeat
scPharmaceuticals (STU:2SX) Cash Flow from Operations : €-64.68 Mil (TTM As of Sep. 2024) - GuruFocus.com
scPharmaceuticals (STU:2SX) Float Percentage Of Total Shares Outstanding : 88.47% (As of Nov. 21, 2024) - GuruFocus.com
scPharmaceuticals (STU:2SX) Intrinsic Value: Projected FCF : €-6.70 (As of Nov. 21, 2024) - GuruFocus.com
scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless - Simply Wall St
Downgrade: Here's How Analysts See scPharmaceuticals Inc. (NASDAQ:SCPH) Performing In The Near Term - Simply Wall St
HC Wainwright Expects Reduced Earnings for scPharmaceuticals - MarketBeat
King Luther Capital Management Corp's Strategic Acquisition in s - GuruFocus.com
Earnings Update: scPharmaceuticals Inc. (NASDAQ:SCPH) Just Reported And Analysts Are Trimming Their Forecasts - Yahoo Finance
500: Something went wrong - Investing.com India
SCPH stock touches 52-week low at $3.24 amid market challenges - Investing.com
scPharmaceuticals Inc. (NASDAQ:SCPH) Q3 2024 Earnings Call Transcript - Insider Monkey
scPharmaceuticals Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
The one-year earnings decline has likely contributed toscPharmaceuticals' (NASDAQ:SCPH) shareholders losses of 33% over that period - Simply Wall St
Earnings call: scPharmaceuticals reports robust Q3 growth, eyes FDA nod By Investing.com - Investing.com UK
ScPharmaceuticals, Inc. (SCPH) Reports Q3 Loss, Lags Revenue Estimates - MSN
scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
scPharmaceuticals Inc (SCPH) Q3 2024 Earnings Call Highlights: R - GuruFocus.com
scPharmaceuticals Inc (SCPH) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance
scPharmaceuticals Reports Strong Growth in Q3 2024 - TipRanks
ScPharmaceuticals Q3 Loss Widens, Revenue Rises - Marketscreener.com
scPharmaceuticals' FUROSCIX Revenue Surges 164% YoY to $10M in Q3, Expands FDA Approval | SCPH Stock News - StockTitan
Certain Common Stock of scPharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 11-NOV-2024. - Marketscreener.com
scPharmaceuticals (SCPH) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat
scPharmaceuticals to Announce Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 - The Manila Times
scPharmaceuticals Sets Q3 2024 Earnings Call for November 13 | SCPH Stock News - StockTitan
scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Acquired by Rice Hall James & Associates LLC - MarketBeat
KING LUTHER CAPITAL MANAGEMENT CORP Expands Stake in scPharmaceu - GuruFocus.com
TD Cowen reiterates Buy rating on scPharmaceuticals stock, highlights optimism for Furoscix approval - Investing.com India
TD Cowen reiterates Buy rating on scPharmaceuticals stock, highlights optimism for Furoscix approval By Investing.com - Investing.com South Africa
Third Time's The Charm For ScPharma? - RTTNews
scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024 - GlobeNewswire
Congestive Heart Failure Treatment Market 2034: Clinical - openPR
The Attractiveness of Investing In scPharmaceuticals Inc (SCPH) is Growing - Knox Daily
Scpharmaceuticals Inc Stock (SCPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
1.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):